FBIO (Fortress Biotech) Beginning Cash Position: $80.60 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FBIO Fortress Biotech Inc FBIO
45 GF Score
Price $3.37
GF Value $1.25
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Fortress Biotech Beginning Cash Position?

Fortress Biotech FBIO -1.90% 45 Beginning Cash Position is $80.60 Mil as of Mar. 2026. GuruFocus rates FBIO with a GF Score™ of 45/100 and a GF Value™ of $1.25 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Fortress Biotech's Beginning Cash Position for the quarter that ended in Mar. 2026 was $80.60 Mil.

Fortress Biotech's quarterly Beginning Cash Position increased from Sep. 2025 ($75.61 Mil) to Dec. 2025 ($87.44 Mil) but then declined from Dec. 2025 ($87.44 Mil) to Mar. 2026 ($80.60 Mil).

Fortress Biotech's annual Beginning Cash Position declined from Dec. 2023 ($180.95 Mil) to Dec. 2024 ($83.37 Mil) and declined from Dec. 2024 ($83.37 Mil) to Dec. 2025 ($58.82 Mil).

Fortress Biotech Beginning Cash Position Related Terms

Fortress Biotech Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Fortress Biotech's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fortress Biotech Beginning Cash Position Chart

Fortress Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 235.00 307.96 180.95 83.37 58.82

Fortress Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.82 92.56 75.61 87.44 80.60
FBIO
45GF Score
Fortress Biotech Inc FBIO
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fortress Biotech Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $80.60 Mil mean?
Fortress Biotech (FBIO) has a Beginning Cash Position of $80.60 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Fortress Biotech and its competitors.
Is Fortress Biotech's Beginning Cash Position too high?
Fortress Biotech's current Beginning Cash Position is $80.60 Mil. Overall, Fortress Biotech has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fortress Biotech's Beginning Cash Position compare to RLYB and INO?
Fortress Biotech's Beginning Cash Position of $80.60 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Fortress Biotech and its competitors. Fortress Biotech's current Beginning Cash Position is $80.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fortress Biotech stock overvalued right now?
Based on GuruFocus' analysis, Fortress Biotech (FBIO) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.25, compared to a current price of $3.37 — trading 169.2% above its estimated fair value. The current Beginning Cash Position is $80.60 Mil. Fortress Biotech's overall GF Score™ is 45/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Fortress Biotech (FBIO), the current Beginning Cash Position is $80.60 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fortress Biotech (FBIO) Overvalued in 2026?

Based on GuruFocus' analysis, Fortress Biotech stock appears to be overvalued. The current stock price of $3.37 is trading 169.2% above its estimated GF Value™ of $1.25. GuruFocus considers Fortress Biotech to be Significantly Overvalued.

Key valuation signals for FBIO:

  • Beginning Cash Position: $80.60 Mil
  • GF Value™: $1.25 vs. price of $3.37 (169.2% above fair value)
  • GF Score™: 45/100 with 7 warning signs

No single metric tells the full story. See the FBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fortress Biotech Business Description

Address 1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
45GF Score

Get the complete analysis for FBIO

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.37
Price
$1.25
GF Value